Abstract
determined by a wound healing assay. In xenografted model (NCI-N87), mice were injected (SC; 200 ug/head, 10 mg/kg or IV; 300 ug/head, 15 mg/kg) with CP-RUNX (HM85R) for 3 weeks. This experiment showed that local or systemic delivery of CP-RUNX3 could significantly reduce tumor growth (p<0.05). p21Cip1/Waf1 and VEGF expression in lung and tumor were also significantly increased and decreased, respectively. Conclusion: These results suggest that In Vivo protein replacement therapy with cell-permeable and tissuedistributable recombinant proteins containing MTD can intervene in an abnormally active or dysfunctional intracellular process. Therefore, we conclude that intracellular delivery of RUNX3 with MTD could be useful for treating gastric cancer.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
